Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Progyny, Inc. (PGNY) SEC filings page on Stock Titan provides direct access to the company’s official U.S. Securities and Exchange Commission documents, along with AI-powered summaries to help interpret the information. Progyny’s common stock is registered under Section 12(b) of the Exchange Act and trades on the Nasdaq Global Select Market, so its filings include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, among others.
For a benefits management company in the healthcare plans sector, annual reports (Form 10-K) and quarterly reports (Form 10-Q) are key sources for understanding revenue from fertility benefit services and pharmacy benefit services, client and member metrics, risk factors, and management’s discussion of operations. AI summaries can highlight how Progyny describes its women’s health and family building solutions, its clinical networks, and the factors that influence utilization and margins.
Current reports on Form 8-K document material events such as quarterly earnings releases, the entry into a revolving credit facility, and executive leadership changes. For example, recent 8-K filings reference financial results for specific quarters, the establishment of a $200 million revolving credit facility under a Credit Agreement, and the planned cessation of employment of the company’s president along with a consulting arrangement. AI analysis can surface the sections that describe these events, summarize their implications, and point to related exhibits.
Investors and analysts interested in executive arrangements, capital structure, and financing can use this page to review disclosures about the revolving credit facility, guarantees by subsidiaries, and covenants such as leverage and interest coverage ratios, as described in the July 1, 2025 Form 8-K. Over time, filings also provide context on stock repurchase authorizations, share-based compensation, and other capital priorities.
The filings page also makes it easier to monitor risk disclosures and regulatory language. Progyny’s safe harbor statements and risk factor summaries discuss competition, client retention, utilization variability, regulatory changes, data security, relationships with providers and pharmacy partners, and other issues that can affect results. With real-time updates from EDGAR and AI-generated explanations, users can quickly locate the most relevant sections of long documents, whether they are reviewing a 10-K, a 10-Q, or a Form 4 related to insider transactions.
Progyny, Inc. (PGNY) filed a Form 144 reporting a proposed sale of 2,398 common shares for an aggregate market value of $55,058.08. The shares are to be sold through Fidelity Brokerage Services on the NASDAQ with an approximate sale date of 08/28/2025. The filing shows 85,982,409 shares outstanding for the class listed.
The securities were acquired on 08/28/2025 through restricted stock vesting and the consideration is listed as compensation. The filer reports no securities sold in the past three months and includes the standard representation that the selling person does not possess undisclosed material adverse information.
Progyny director GORDON KEVIN K reported a sale of 2,500 common shares on 08/11/2025 at a price of $22.035. The filing shows 12,501 shares are beneficially owned indirectly by the Kevin Gordon Revocable Declaration of Trust, for which the reporting person serves as trustee.
The form's explanation states 5,147 shares were transferred into that Trust on June 2, 2025 from shares previously reported as directly held. The filing also includes a table entry listing 8,026 shares with a disposition marker but no date or price shown for that line.
Progyny (PGNY) filed a Form 144 notifying a proposed sale of 2,500 shares of its common stock, with an aggregate market value of $55,087.50, through Fidelity Brokerage Services LLC on 08/11/2025. The shares were acquired on 10/24/2021 via restricted stock vesting and were granted as compensation; the filer reports no securities sold in the past three months.
The filing includes the issuer's outstanding share count of 85,982,409, making the proposed sale a very small fraction of outstanding stock. The notice includes the filer’s representation that no undisclosed material adverse information about the issuer is known.
Progyny (PGNY) filed its Q2-25 10-Q showing solid top-line momentum and margin expansion, tempered by higher opex and tax expense.
- Revenue rose 9.5% YoY to $332.9 m; pharmacy contributed 36% while core fertility benefits grew 10.5%. 1H-25 revenue is up 12.9% to $656.9 m.
- Gross profit improved 15.7% to $79.0 m; gross margin expanded 130 bp to 23.7% as case-rate pricing and pharmacy rebates offset service-cost inflation.
- Operating income increased 17.7% to $24.4 m; however, a higher effective tax rate (36.8% vs 34.2%) limited net income growth to 3.8% ($17.1 m, $0.19 diluted EPS).
- For 1H-25, net income slipped 3.6% to $32.2 m, but diluted EPS rose to $0.36 on a 10% lower share count following 2024 buybacks.
- Cash & M-secs stand at $305.1 m, up $18.1 m YoY; operating cash flow strengthened 28% to $105.3 m. No debt; a new $200 m undrawn revolver was signed 1 Jul 25.
- Balance sheet: current ratio 2.7x; equity climbed 22% to $515.0 m. Accounts receivable (+16%) and payables (+48%) rose with volume.
- Operations: ART cycles grew 8.8% to 16,938 while overall member utilization held at 0.55%. Client count reached 542 covering 6.8 m lives.
- M&A: closed $10.5 m Benefit Bump acquisition in Jan-25; integration ongoing.
Overall, PGNY continues to outpace the fertility-benefits market, generating healthy cash and maintaining a debt-free profile, though investors should watch rising opex, receivables exposure and tax headwinds.